FDA Nods PYC Therapeutics’ Eye Disease Drug

PYC Therapeutics Limited (AU:PYC) has released an update.

PYC Therapeutics has announced that the FDA has awarded its PYC-001 drug program, aimed at treating a rare pediatric blinding eye disease, the Rare Pediatric Disease designation. As a result, the company may be eligible for a Priority Review Voucher upon the drug’s approval, potentially expediting future product reviews. The designation underlines the significant unmet need for a treatment, as no current options exist for Autosomal Dominant Optic Atrophy, which affects about 1 in 35,000 people.

For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.